City of Hope (T Cell Manufacturing)

Duarte, CA
National Center
CAR-T Cell Therapy
206 confirmed programs · 129 sponsors · Last scored 2026-04-02
84.9
Signal Score
✓ FDA Inspections (2) ✓ Clinical Trials (206) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: City of Hope (T Cell Manufacturing)

Signal Score
84.9/100 (as of 2026-04-02)
Quality Compliance
100.0/100
Headquarters
Duarte, CA
Modalities
CAR-T, Cell Therapy
Active Programs
206 confirmed from ClinicalTrials.gov across 129 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
FDA Inspections2 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-02-07)
Operations 99.0
206 active programs across 129 sponsors
Modalities: Cell Therapy, CAR-T
127 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
206 active programs across 129 sponsors · Modalities: Cell Therapy, CAR-T · 127 programs in advanced phases (Phase 2/3)
Programs 206
Sponsors129
ModalitiesCAR-T, Cell Therapy
206 active programs across 129 sponsors
Modalities: Cell Therapy, CAR-T
127 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07387367 A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment... PHASE3 Recruiting
NCT07219212 A Study of JNJ-90301900 in Combination With Chemoradiation... PHASE1 Recruiting
NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients... PHASE1/PHASE2 Recruiting
NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the... PHASE1 Recruiting
NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the... PHASE1 Recruiting
NCT06976736 A Long Term Follow-up Study of TScan TCR-T Products NA Recruiting
NCT06859424 A Platform Protocol to Investigate Post-Transplant... PHASE2 Recruiting
NCT07038447 A Study of KITE-363 in Participants With Refractory... PHASE1 Enrolling By Invitation
NCT06552416 Safety of MT-401-OTS in Patients With Relapsed AML or MDS PHASE1 Recruiting
NCT06533579 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) PHASE1/PHASE2 Recruiting
View all 206 programs →
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability 68.0
Parent company: City of Hope
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: City of Hope
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Duarte, CA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

FDA Inspection History

2025-02
2024-12
NAI VAI OAI
Date Site Type Observations Classification
2025-02-07 Duarte, California Human Cellular, Tissue, and Gene Therapies No No Action Indicated (NAI)
2024-12-09 Irvine, California Blood and Blood Products No No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Apr 05, 2026

Clinical Activity 206 studies

NCT07387367 A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus... PHASE3 Recruiting NCT07219212 A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in... PHASE1 Recruiting NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration... PHASE1/PHASE2 Recruiting NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of... PHASE1 Recruiting NCT04119024 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of... PHASE1 Recruiting NCT06976736 A Long Term Follow-up Study of TScan TCR-T Products NA Recruiting NCT06859424 A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based... PHASE2 Recruiting NCT07038447 A Study of KITE-363 in Participants With Refractory Autoimmune Diseases PHASE1 Enrolling By Invitation NCT06552416 Safety of MT-401-OTS in Patients With Relapsed AML or MDS PHASE1 Recruiting NCT06533579 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) PHASE1/PHASE2 Recruiting NCT06657144 A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other... PHASE1 Recruiting NCT06805305 DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult... PHASE2 Recruiting NCT06528301 A Phase 1 Study of UB-VV111 With and Without Rapamycin in... PHASE1 Recruiting NCT06514794 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in... PHASE2 Recruiting NCT06699212 A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in... PHASE3 Recruiting NCT06667076 A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in... PHASE2 Recruiting NCT06577025 A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With... PHASE2 Active Not Recruiting NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic... PHASE1/PHASE2 Recruiting NCT06163534 A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head &... NA Recruiting NCT06500273 Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL PHASE2 Recruiting
+ 186 more studies
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
Cellares
South San Francisco, CA
Signal Score: 67.0
CAR-T, Cell Therapy
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.7
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.5
CAR-T, Cell Therapy